Review
Published · Updated · 1 min read
Targeted therapy for metastatic NSCLC: sunvozertinib superiority and sustained lorlatinib efficacy
What it means for practice
The review emphasizes comprehensive molecular profiling in metastatic NSCLC. Pralsetinib's benefits should be considered alongside the safety concerns noted in the source.
Summary
The review summarizes key findings presented at the 2026 American Society of Clinical Oncology (ASCO) meeting on metastatic non-small-cell lung cancer (NSCLC) with oncogene addiction. It focuses on targeted therapies for tumors with EGFR, ALK, and RET alterations.
Key findings
- Sunvozertinib: the phase III WU-KONG28 trial demonstrated superiority over platinum-based chemotherapy in patients with tumors harboring EGFR exon 20 insertions.
- Amivantamab and lazertinib: the combination showed promising survival benefits in atypical EGFR mutations.
- Lorlatinib: the CROWN trial confirmed long-term efficacy in ALK-positive NSCLC.
- Pralsetinib: the AcceleRET-Lung trial demonstrated superiority over chemotherapy in RET fusion cases, while also noting safety concerns.
Practice implications and limits of the available data
The authors emphasize the expanding role of targeted therapies in NSCLC and the need for comprehensive molecular profiling. The available abstract provides no sample sizes, quantitative effect estimates, follow-up durations, or details of the safety concerns associated with pralsetinib. It therefore does not allow assessment of the magnitude of benefit or a detailed evaluation of the benefit–risk balance.
Source
-
CBNPC métastatiques avec addiction oncogénique.
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer